Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression

Advances in Cancer Research

Volumn 123, Issue , 2014, Pages 67-94

  Adamia, Sophia ^a   Kriangkum, Jitra ^b   Belch, Andrew R ^b   Pilarski, Linda M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aberrant splicing; Alternative splicing; B cell malignancies; Hyaluronan synthase 1; Intracellular hyaluronan; Mitotic catastrophe; Oncogenic events; RHAMM

Indexed keywords

HYALURONATE SYNTHETASE; SYNTHETASE; UNCLASSIFIED DRUG; GLUCURONOSYLTRANSFERASE; GREEN FLUORESCENT PROTEIN; HYALURONAN SYNTHASE; MESSENGER RNA;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; ENZYME ANALYSIS; GENETIC STABILITY; HUMAN; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; TUMOR GROWTH; ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC VARIABILITY; GENETICS; METABOLISM; MITOSIS; MOLECULAR GENETICS; MOUSE; MUTATION; NEOPLASM; PATHOLOGY; RNA PROCESSING; SPINDLE APPARATUS; TREATMENT OUTCOME;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; GLUCURONOSYLTRANSFERASE; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MITOSIS; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; MUTATION; NEOPLASMS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; SPINDLE APPARATUS; TREATMENT OUTCOME;

EID: 84904862424     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800092-2.00003-4     Document Type: Chapter

References (88)

1. Abrahamsson A.E., Geron I., Gotlib J., Dao K.H., Barroga C.F., Newton I.G., et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:3925-3929.
2. Adamia S., Crainie M., Kriangkum J., Mant M.J., Belch A.R., Pilarski L.M. Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia. Seminar in Oncology 2003, 30:165-168.
3. Adamia S., Haibe-Kains B., Pilarski P.M., Bar-Natan M., Pevzner S., Avet-Loiseau H., et al. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clinical Cancer Research 2014, 20(5):1135-1145.
4. Adamia S., Maxwell C.A., Pilarski L.M. Hyaluronan and hyaluronan synthases: Potential therapeutic targets in cancer. Current Drug Targets: Cardiovascular & Haematological Disorders 2005, 5:3-14.
5. Adamia S., Pilarski P.M., Bar-Natan M., Stone R.M., Griffin J.D. Alternative splicing in chronic myeloid leukemia (CML): A novel therapeutic target?. Current Cancer Drug Targets 2013, 13:735-748.
6. Adamia S., Pilarski P.M., Belch A.R., Pilarski L.M. Genetic abnormalities in Waldenstrom's macroglobulinemia. Clinical Lymphoma & Myeloma 2009, 9:30-32.
7. Adamia S., Pilarski P.M., Belch A.R., Pilarski L.M. Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets. Current Cancer Drug Targets 2013, 13:347-361.
8. Adamia S., Reichert A.A., Kuppusamy H., Kriangkum J., Ghosh A., Hodges J.J., et al. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. Blood 2008, 112:5111-5121.
9. Adamia S., Reiman T., Crainie M., Mant M.J., Belch A.R., Pilarski L.M. Intronic splicing of hyaluronan synthase 1 (HAS1): A biologically relevant indicator of poor outcome in multiple myeloma. Blood 2005, 105:4836-4844.
10. Adamia S., Treon S.P., Reiman T., Tournilhac O., McQuarrie C., Mant M.J., et al. Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia. Clinical Lymphoma 2005, 5:253-256.
11. Almeida J., Orfao A., Mateo G., Ocqueteau M., Garcia-Sanz R., Moro M.J., et al. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Pathologie Biologie (Paris) 1999, 47:119-127.
12. Amara F.M., Entwistle J., Kuschak T.I., Turley E.A., Wright J.A. Transforming growth factor-beta1 stimulates multiple protein interactions at a unique cis-element in the 3'-untranslated region of the hyaluronan receptor RHAMM mRNA. Journal of Biological Chemistry 1996, 271:15279-15284.
13. Assmann V., Jenkinson D., Marshall J.F., Hart I.R. The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. Journal of Cell Science 1999, 112(Pt. 22):3943-3954.
14. Assmann V., Marshall J.F., Fieber C., Hofmann M., Hart I.R. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. Journal of Cell Science 1998, 111(Pt. 12):1685-1694.
15. Ast G. How did alternative splicing evolve? Nature reviews. Genetics 2004, 5:773-782.
16. Avet-Loiseau H., Andree-Ashley L.E., Moore D., Mellerin M.P., Feusner J., Bataille R., et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes, Chromosomes & Cancer 1997, 19:124-133.
17. Bahlis N.J. Darwinian evolution and tiding clones in multiple myeloma. Blood 2012, 120:927-928.
18. Bansal M.K., Mason R.M. Evidence for rapid metabolic turnover of hyaluronate synthetase in Swarm rat chondrosarcoma chondrocytes. The Biochemical Journal 1986, 236:515-519.
19. Bharadwaj A.G., Goodrich N.P., McAtee C.O., Haferbier K., Oakley G.G., Wahl J.K., et al. Hyaluronan suppresses prostate tumor cell proliferation through diminished expression of N-cadherin and aberrant growth factor receptor signaling. Experimental Cell Research 2011, 317:1214-1225.
20. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annual Review of Biochemistry 2003, 72:291-336.
21. Brown R.L., Reinke L.M., Damerow M.S., Perez D., Chodosh L.A., Yang J., et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. The Journal of Clinical Investigation 2011, 121:1064-1074.
22. Carter S.L., Eklund A.C., Kohane I.S., Harris L.N., Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nature Genetics 2006, 38:1043-1048.
23. Cazzola M., Rossi M., Malcovati L. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood 2013, 121:260-269.
24. Choi J.W., Kim D.G., Lee A.-E., Kim H.R., Lee J.Y., Kwon N.H., et al. Cancer-associated splicing variant of tumor suppressor AIMP2/p38: Pathological implication in tumorigenesis. PLoS Genetics 2011, 7:e1001351.
25. Crainie M., Belch A.R., Mant M.J., Pilarski L.M. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: Identification of three distinct RHAMM variants. Blood 1999, 93:1684-1696.
26. David A., Mabjeesh N., Azar I., Biton S., Engel S., Bernstein J., et al. Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. Journal of Biological Chemistry 2002, 277:18084-18090.
27. de Anta J.M., Mayo C., Sole F., Salido M., Espinet B., Corzo C., et al. Methotrexate resistance in vitro is achieved by a dynamic selection process of tumor cell variants emerging during treatment. International Journal of Cancer 2006, 119:1607-1615.
28. Debes Marun C.S., Belch A.R., Pilarski L.M. In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival. American Journal of Hematology 2012, 87:579-587.
29. Farina A.R., Tacconelli A., Cappabianca L., Cea G., Chioda A., Romanelli A., et al. The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells. Oncogene 2009, 28:4075-4094.
30. Ghadimi B.M., Sackett D.L., Difilippantonio M.J., Schrock E., Neumann T., Jauho A., et al. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes, Chromosomes & Cancer 2000, 27:183-190.
31. Ghosh A., Kuppusamy H., Pilarski L.M. Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: A potential mechanism promoting human cancer. Journal of Biological Chemistry 2009, 284:18840-18850.
32. Golshani R., Hautmann S.H., Estrella V., Cohen B.L., Kyle C.C., Manoharan M., et al. HAS1 expression in bladder cancer and its relation to urinary HA test. International Journal of Cancer 2007, 120:1712-1720.
33. Gutierrez N.C., Garcia J.L., Hernandez J.M., Lumbreras E., Castellanos M., Rasillo A., et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004, 104:2661-2666.
34. Hamilton S.R., Fard S.F., Paiwand F.F., Tolg C., Veiseh M., Wang C., et al. The hyaluronan receptors CD44 and RHAMM (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. Journal of Biological Chemistry 2007, 282:16667-16680.
35. Hardwick C., Hoare K., Owens R., Hohn H.P., Hook M., Moore D., et al. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. Journal of Cell Biology 1992, 117:1343-1350.
36. Hartsough E.J., Basile K., Aplin A.E. Beneficial effects of raf inhibitor in mutant BRAF splice variant-expressing melanoma. Molecular Cancer Research 2014, 12(5):795-802.
37. Iacobucci I., Lonetti A., Messa F., Cilloni D., Arruga F., Ottaviani E., et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: Implications for a new mechanism of resistance. Blood 2008, 112:3847-3855.
38. Keats J.J., Maxwell C.A., Taylor B.J., Hendzel M.J., Chesi M., Bergsagel P.L., et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 2005, 105:4060-4069.
39. Kirshner J., Thulien K.J., Martin L.D., Debes Marun C., Reiman T., Belch A.R., et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008, 112:2935-2945.
40. Klein F., Feldhahn N., Herzog S., Sprangers M., Mooster J.L., Jumaa H., et al. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 2006, 25:1118-1124.
41. Kops G.J.P.L., Weaver B.A.A., Cleveland D.W. On the road to cancer: Aneuploidy and the mitotic checkpoint. Nature Reviews Cancer 2005, 5:773-785.
42. Kriangkum J., Warkentin A., Belch A.R., Pilarski L.M. Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes. PLoS One 2013, 8:e53469.
43. Kuo M.T., Vyas R.C., Jiang L.X., Hittelman W.N. Chromosome breakage at a major fragile site associated with P-glycoprotein gene amplification in multidrug-resistant CHO cells. Molecular and Cellular Biology 1994, 14:5202-5211.
44. Lingle W.L., Barrett S.L., Negron V.C., D'Assoro A.B., Boeneman K., Liu W., et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:1978-1983.
45. Lo T.C., Barnhill L.M., Kim Y., Nakae E.A., Yu A.L., Diccianni M.B. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leukemia Research 2009, 33:1562-1566.
46. Lu X., Feng X., Man X., Yang G., Tang L., Du D., et al. Aberrant splicing of Hugl-1 is associated with hepatocellular carcinoma progression. Clinical Cancer Research 2009, 15:3287-3296.
47. Lugli A., Zlobec I., Gunthert U., Minoo P., Baker K., Tornillo L., et al. Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Modern Pathology 2006, 19:1302-1309.
48. Masellis-Smith A., Belch A.R., Mant M.J., Turley E.A., Pilarski L.M. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: Alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood 1996, 87:1891-1899.
49. Matera A.G., Wang Z. A day in the life of the spliceosome. Nature Reviews Molecular Cell Biology 2014, 15:108-121.
50. Matlin A.J., Clark F., Smith C.W. Understanding alternative splicing: Towards a cellular code. Nature Reviews Molecular Cell Biology 2005, 6:386-398.
51. Maxwell C.A., Keats J.J., Belch A.R., Pilarski L.M., Reiman T. Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Research 2005, 65:850-860.
52. Maxwell C.A., Keats J.J., Crainie M., Sun X., Yen T., Shibuya E., et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Molecular Biology of the Cell 2003, 14:2262-2276.
53. Maxwell C.A., McCarthy J., Turley E. Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions?. Journal of Cell Science 2008, 121:925-932.
54. Maxwell C.A., Rasmussen E., Zhan F., Keats J.J., Adamia S., Strachan E., et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 2004, 104:1151-1158.
55. Mian N. Analysis of cell-growth-phase-related variations in hyaluronate synthase activity of isolated plasma-membrane fractions of cultured human skin fibroblasts. The Biochemical Journal 1986, 237:333-342.
56. Mohapatra S., Yang X., Wright J.A., Turley E.A., Greenberg A.H. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. Journal of Experimental Medicine 1996, 183:1663-1668.
57. Nagel S., Hirschmann P., Dirnhofer S., Gunthert U., Tzankov A. Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. Experimental Hematology 2010, 38:38-45.
58. Ocqueteau M., Orfao A., Almeida J., Blade J., Gonzalez M., Garcia-Sanz R., et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. The American Journal of Pathology 1998, 152:1655-1665.
59. Perez de Castro I., de Carcer G., Malumbres M. A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy. Carcinogenesis 2007, 28:899-912.
60. Pilarski L.M., Adamia S., Maxwell C.A., Pilarski P.M., Reiman T., Belch A.R. Hyaluronan synthases and RHAMM as synergistic mediators of malignancy in B lineage cancers. Hyaluronan structure, metabolism, biological activities, therapeutic applications 2005, 329-338. Matrix Biology Institute, Edgewater, New Jersey, USA. E.A. Balazs, V.C. Hascall (Eds.).
61. Pilarski L.M., Belch A.R. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clinical Cancer Research 2002, 8:3198-3204.
62. Pilarski L.M., Debes Marun C.S., Martin L.D., Venner C.P., Pilarski P.M., Belch A.R. B lymphocytes as cancer stem cells in multiple myeloma. The Journal of OncoPathology 2013, 1:10-21.
63. Pilarski L.M., Giannakopoulos N.V., Szczepek A.J., Masellis A.M., Mant M.J., Belch A.R. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Clinical Cancer Research 2000, 6:585-596.
64. Pilarski L.M., Hipperson G., Seeberger K., Pruski E., Coupland R.W., Belch A.R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: Engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000, 95:1056-1065.
65. Pilarski L.M., Mant M.J., Belch A.R. Circulating monoclonal multi-drug resistant B cells may comprise the malignant stem cells population in multiple myeloma. Challenges in modern medicine 1994, Vol 4:31-39. Ares Serono Symposia, Rome, Italy. F. Dammaco, B. Barlogie (Eds.).
66. Pilarski L.M., Masellis-Smith A., Belch A.R., Yang B., Savani R.C., Turley E.A. RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: A mediator in B cell malignancy?. Leukemia and Lymphoma 1994, 14:363-374.
67. Pilarski L.M., Pruski E., Wizniak J., Paine D., Seeberger K., Mant M.J., et al. Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Blood 1999, 93:2918-2927.
68. Pilarski L.M., Reiman T., Pilarski P.M., Orr F.W., Belch A.R. The malignant hierarchy in multiple myeloma: Relationships between malignant cells and bone disease. Bone metastasis and molecular mechanisms: Pathophysiology 2004, 109-138. Kluwer Academic Publishers, The Netherlands. G. Singh, F.W. Orr (Eds.).
69. Romano M., Buratti E., Baralle D. Role of pseudoexons and pseudointrons in human cancer. International Journal of Cell Biology 2013, 2013:810572.
70. Roy B., Haupt L.M., Griffiths L.R. Review: Alternative splicing (AS) of genes as an approach for generating protein complexity. Current Genomics 2013, 14:182-194.
71. Shi Y., Reiman T., Li W., Maxwell C.A., Sen S., Pilarski L., et al. Targeting aurora kinases as therapy in multiple myeloma. Blood 2007, 109:3915-3921.
72. Shkreta L., Bell B., Revil T., Venables J.P., Prinos P., Elela S.A., et al. Cancer-associated perturbations in alternative pre-messenger RNA splicing. Cancer Treatment and Research 2013, 158:41-94.
73. Snijders A.M., Hermsen M.A., Baughman J., Buffart T.E., Huey B., Gajduskova P., et al. Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability. Genes, Chromosomes & Cancer 2008, 47:71-83.
74. Spinelli R., Pirola A., Redaelli S., Sharma N., Raman H., Valletta S., et al. Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases. Molecular Genetics and Genomic Medicine 2013, 1:246-259.
75. Stark M., Wichman C., Avivi I., Assaraf Y.G. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009, 113:4362-4369.
76. Swanton C., Tomlinson I., Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 2006, 5:818-823.
77. Telmer P.G., Tolg C., McCarthy J.B., Turley E.A. How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression?. Communicative and Integrative Biology 2011, 4:182-185.
78. Till K.J., Zuzel M., Cawley J.C. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Research 1999, 59:4419-4426.
79. Tlapak-Simmons V.L., Baggenstoss B.A., Clyne T., Weigel P.H. Purification and lipid dependence of the recombinant hyaluronan synthases from Streptococcus pyogenes and Streptococcus equisimilis. Journal of Biological Chemistry 1999, 274:4239-4245.
80. Tolg C., Hamilton S.R., Morningstar L., Zhang J., Zhang S., Esguerra K.V., et al. RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. Journal of Biological Chemistry 2010, 285:26461-26474.
81. Turley E.A., Belch A.J., Poppema S., Pilarski L.M. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes. Blood 1993, 81:446-453.
82. Tzankov A., Strasser U., Dirnhofer S., Menter T., Arber C., Jotterand M., et al. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival. Annals of Hematology 2011, 90:901-909.
83. Vassen L., Khandanpour C., Ebeling P., van der Reijden B.A., Jansen J.H., Mahlmann S., et al. Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. International Journal of Hematology 2009, 89:422-430.
84. Wappenschmidt B., Becker A.A., Hauke J., Weber U., Engert S., Kohler J., et al. Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction. PLoS One 2012, 7:e50800.
85. Weaver B.A.A., Silk A.D., Montagna C., Verdier-Pinard P., Cleveland D.W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007, 11:25-36.
86. Wolfe K.H., Sharp P.M., Li W.H. Mutation rates differ among regions of the mammalian genome. Nature 1989, 337:283-285.
87. Yang G., Huang S.C., Wu J.Y., Benz E.J. Regulated Fox-2 isoform expression mediates protein 4.1R splicing during erythroid differentiation. Blood 2008, 111:392-401.
88. Zlobec I., Baker K., Terracciano L.M., Lugli A. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clinical Cancer Research 2008, 14:3798-3806.